JOIN USScientists have sequenced genome of a malaria parasite that constitutes about 65 per cent malaria cases in India, paving the way for new vaccines to combat the disease.
The National Institute of Malaria Research in India was a part of the study which focused on Plasmodium vivax (P.vivax), a species of malaria that afflicts humans and the most prevalent human malaria parasite outside Africa.
P. vivax malaria constitutes about 60–65 per cent of total malaria cases in India.
The study was led by Jane Carlton, part of New York University’s Center for Genomics and Systems Biology.
“The bad news is there is significantly more genetic variation in P. vivax than we’d thought, which could make it quite adept at evading whatever arsenal of drugs and vaccines we throw at it,” Carlton who is also heading the International Center of Excellence for Malaria Research (ICEMR) based in India.
“However, now that we have a better understanding of the challenges we face, we can move forward with a deeper analysis of its genomic variation in pursuing more effective remedies,” Carlton said in a statement.
The researchers examined P. vivax strains from different geographic locations in West Africa, South America, and Asia, providing the researchers with the first genome-wide perspective of global variability within this species.
Their analysis showed that P. vivax has twice as much genetic diversity as the world-wide Plasmodium falciparum (P. falciparum) strains, revealing an unexpected ability to evolve and, therefore, presenting new challenges in the search for treatments.
Researchers from The Broad Institute, Arizona State University, and the Centers for Disease Control and Prevention were also part of the P. vivax sequencing.
In another study by Carlton with Professor Kazuyuki Tanabe at Osaka University, Japan, researchers have for the first time sequenced Plasmodium cynomolgi genomes.